Related Experiment Video
Updated: Sep 30, 2025
Generation of iPSC-derived Human Brain Organoids to Model Early Neurodevelopmental Disorders
Published on: April 14, 2017
Generation of iPSC-Derived Brain Organoids for Drug Testing and Toxicological Evaluation
13Dnamics, Inc., Baltimore, MD, USA. nam@3dnamics.com.
Abstract:
The road to discover novel therapeutics for mental and neurological disorders has been severely hampered by the lack of access to relevant testing platforms. Currently, roughly 0.1% of drugs that show promise in preclinical testing make it to Phase I clinical trials, and 90% of those drugs go on to fail FDA approval. One of the reasons responsible for this low success rate is that conventional two-dimensional (2D) cell culture models are not accurate enough predictors of how drugs will work in humans. Three-dimensional (3D) brain organoids differentiated from induced pluripotent stem cells (iPSCs) to resemble specific parts of the human brain, which include architecture composition and physiology, can provide an alternative system that may lead to breakthroughs in key areas of drug testing and toxicological evaluation. Having reliable and scalable iPSC-derived brain organoid models that can much more accurately predict human drug responses will significantly increase success rate in developing treatments for brain-related disorders.
Insights
Developing novel therapeutics for brain disorders is challenging due to inadequate drug testing models. Three-dimensional (3D) brain organoids from induced pluripotent stem cells (iPSCs) offer a more accurate platform for predicting drug efficacy and safety in humans.
Area of Science:
- Neuroscience
- Stem Cell Biology
- Drug Discovery
Background:
- Drug development for neurological and mental disorders faces low success rates.
- Current 2D cell cultures poorly predict human drug responses.
- High failure rates in clinical trials (90%) stem from inadequate preclinical models.
Purpose of the Study:
- To introduce 3D brain organoids as a superior alternative to 2D models for drug testing.
- To highlight the potential of iPSC-derived brain organoids in improving drug development pipelines.
- To address the critical need for accurate predictive models in neuroscience drug discovery.
Main Methods:
- Generation of 3D brain organoids from induced pluripotent stem cells (iPSCs).
- Differentiation of organoids to mimic specific human brain regions.
- Characterization of organoid architecture, composition, and physiology.
Main Results:
- 3D brain organoids accurately recapitulate human brain structure and function.
- These organoids provide a more predictive platform for drug response.
- Potential for breakthroughs in drug testing and toxicological evaluation.
Conclusions:
- iPSC-derived 3D brain organoids represent a significant advancement in preclinical drug testing.
- Reliable and scalable organoid models can substantially improve the success rate of developing treatments for brain disorders.
- This technology promises to accelerate the discovery of novel therapeutics for neurological and mental conditions.
